Insider Cluster (3 insiders) ·Filed May 13, 2026

ZTS

Zoetis Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $653K total
Actionable Insight • Neutral

This cluster of buys is economically trivial and should not be read as a bullish signal. The $653K outlay by two directors is routine portfolio adjustment. Monitor for any pending earnings or pipeline catalyst, but the insider activity itself offers no actionable edge.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
ZTS ▼ -0.58% at T+60d
NEUTRAL call ✗ call lost -0.58% · α vs SPY -3.91% · entry $75.24 → $74.80
Entry anchored
May 13, 03:59 PM ET
via exchange tick
T+1d
-2.15%
call -2.15% · α -0.93%
$73.62
settled 5mo ago
T+5d
+6.30%
call +6.30% · α +7.02%
$79.98
settled 5mo ago
T+20d
+5.76%
call +5.76% · α +6.61%
$79.57
settled 4mo ago
T+60d
-0.58%
call -0.58% · α -3.91%
$74.80
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Two Zoetis directors made open-market purchases totaling $653K on May 13, 2026, a modest 0.002% of market cap. Director Parent exercised non-cash derivative conversions on May 20 with zero economic outlay. The cluster buys are trivial relative to the $33.4B market cap and do not signal material insider conviction.

Key Financial Metrics

Direction
buying
Total Value
$653.0K
Insiders
3

Key Facts

  • Two directors (Damelio, Bisaro) purchased 8,700 shares for $653K on May 13
  • Director Parent exercised 14,075 derivative shares at $0 on May 20 (non-cash)
  • Total cluster dollar value of $653K equals ~0.002% of $33.4B market cap
  • 30-day insider activity shows only $886K in total purchases prior to this cluster
  • No cash sales occurred in the cluster window

Financial Impact

Open-market buys of $653K are de minimis — far below any materiality threshold for a $33.4B company

insider ownership

Risk Factors

  • Insider purchases may simply reflect personal portfolio diversification at a stock beaten down from prior levels

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ZTS-1779396569350
6 reports for ZTS
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +38.76%Feb 27, 2026
Filters
Rows
Reports for ZTS — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
8-K
BEARISH ★ 7/10
$77.05 $76.29▲ +0.99%▲ +1.58%$69.39 (+9.94%)
May 20, 2026
19w ago
8-K
NEUTRAL ★ 2/10
$79.98 $78.71▼ −1.59%▼ −2.13%$69.39 (−13.24%)
May 13, 2026
20w ago
Insider Cluster
NEUTRAL ★ 2/10
$75.24 $79.57▲ +5.76%▲ +6.61%$69.39 (−7.77%)
May 7, 2026
21w ago
8-K
BEARISH ★ 7/10
$87.24 $77.59▲ +11.06%▲ +14.20%$69.39 (+20.46%)
Apr 8, 2026
25w ago
DEFA14A
NEUTRAL ★ 2/10
$119.65 $112.54▼ −5.94%▼ −14.49%$69.39 (−42.01%)
Feb 27, 2026
31w ago
Court Ruling
BEARISH ★ 6/10
$131.02 $113.27▲ +13.55%▲ +5.99%$69.39 (+47.04%)
Showing 6 of 6

US Market Status

Market Open — Closes in 3h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 21, 2026